行情

NTEC

NTEC

Intec Pharma
NASDAQ

实时行情|Nasdaq Last Sale

1.150
+0.245
+27.13%
盘前: 1.150 0 0.00% 08:34 09/16 EDT
开盘
0.9100
昨收
0.9046
最高
1.380
最低
0.9020
成交量
831.14万
成交额
--
52周最高
9.25
52周最低
0.4100
市值
2,998.65万
市盈率(TTM)
-2.7947
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NTEC 新闻

  • 本周开庭!苹果拟对抗欧盟140亿美元天价税单
  • 新浪科技.5小时前
  • 沪指震荡微跌 沙特石油设施遇袭、油价一度跳升20%
  • 新浪财经.5小时前
  • 沙特阿美据称仍在推进IPO工作 尽管设施受到重创
  • 新浪财经综合.5小时前
  • 若沙特局势恶化 韩国将考虑释放战略石油储备
  • 新浪财经综合.5小时前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

NTEC 简况

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
展开

Webull提供Intec Pharma Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。